Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis.

BACKGROUND Pulmonary hypertension (PH) associated with pulmonary fibrosis (PF) is a severe condition with poor outcome. It is unknown whether patients with PF with associated PH (APH) represent a distinct phenotype of the disease. We hypothesized that the lung tissue gene expression pattern of patients with APH has a characteristic profile when compared with patients with PF without APH. We sought to determine if different gene expression signatures in PF could be determined based on pulmonary arterial pressures (PAPs) and to provide new insights into the pathobiology of APH. METHODS Microarray analysis (Affymetrix) was performed after RNA was extracted from explanted lungs in 116 consecutive patients with PF (development set, n = 84; validation set, n = 32) and seven subjects with idiopathic pulmonary arterial hypertension undergoing lung transplant (LTx). PAP were recorded intraoperatively immediately before starting LTx. The development set was divided into three groups according to mean PAP (mPAP): severe PH group (mPAP ≥ 40 mm Hg, n = 17); intermediate PH group (mPAP 21-39 mm Hg, n = 45); NoPH group (mPAP ≤ 20 mm Hg, n = 22). RESULTS Distinct gene signatures were observed. Patients in the severe PH group showed increased expression of genes, gene sets, and networks related to myofibroblast proliferation and vascular remodeling, whereas patients in the NoPH group strongly expressed proinflammatory genes. Two-dimensional hierarchic clustering based on 222 differentially expressed genes (severe PH vs no PH) dichotomized subjects into two phenotypes in the intermediate PH group and in the validation set. Real-time polymerase chain reaction confirmed the differential expression of selected genes. CONCLUSIONS Gene expression profiles distinguish PF phenotypes with and without APH. This observation can have important implications for future trials.

[1]  L. Farkas,et al.  Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. , 2011, American journal of respiratory cell and molecular biology.

[2]  C. Deutschman,et al.  Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. , 2011, Chest.

[3]  James Lyons-Weiler,et al.  Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. , 2011, Arthritis and rheumatism.

[4]  D. Lynch,et al.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[5]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[6]  M. Humbert,et al.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[7]  M. Maitland,et al.  Inflammation, growth factors, and pulmonary vascular remodeling. , 2009, Journal of the American College of Cardiology.

[8]  Horst Olschewski,et al.  Diagnosis and assessment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[9]  A Berghold,et al.  Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review , 2009, European Respiratory Journal.

[10]  S. Venkatesan,et al.  Pulmonary hypertension in rheumatoid arthritis--relation with the duration of the disease. , 2008, International journal of cardiology.

[11]  J. Ryu,et al.  Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis , 2008, European Respiratory Journal.

[12]  Naftali Kaminski,et al.  MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis , 2008, PLoS medicine.

[13]  S. Nathan,et al.  Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. , 2008, Chest.

[14]  S. Keshavjee,et al.  Outcomes after lung retransplantation in the modern era. , 2008, American journal of respiratory and critical care medicine.

[15]  S. Nathan,et al.  Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant , 2007, European Respiratory Journal.

[16]  A. Borczuk,et al.  Pulmonary hypertension in idiopathic pulmonary fibrosis. , 2007, Chest.

[17]  S. Nathan,et al.  Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. , 2007, American journal of respiratory and critical care medicine.

[18]  B. Han,et al.  Long pentraxin 3 in pulmonary infection and acute lung injury. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[19]  M. Mishima,et al.  Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. , 2007, Chest.

[20]  S. Nathan,et al.  Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. , 2007, Chest.

[21]  P. Pellikka,et al.  Pulmonary hypertension in patients with interstitial lung diseases. , 2007, Mayo Clinic proceedings.

[22]  K. Wilson,et al.  Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. , 2006, Chest.

[23]  S. Nathan,et al.  The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. , 2006, Respiratory medicine.

[24]  F. D'Ovidio,et al.  Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[25]  M. Selman,et al.  Matrix metalloproteases in aberrant fibrotic tissue remodeling. , 2006, Proceedings of the American Thoracic Society.

[26]  H. Collard,et al.  Classification and Natural History of the Idiopathic Interstitial Pneumonias Who Is at Risk of Ipf? What Causes Ipf? , 2022 .

[27]  J. Behr,et al.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease. , 2006, American journal of respiratory and critical care medicine.

[28]  S. Nathan,et al.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. , 2006, Chest.

[29]  J. Loscalzo,et al.  Pulmonary arterial hypertension. , 2004, Annals of medicine.

[30]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Naftali Kaminski,et al.  Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis , 2005, PLoS medicine.

[32]  S. Nathan,et al.  Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics , 2005, European Respiratory Journal.

[33]  Takashi Suzuki,et al.  Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. , 2004, American journal of respiratory and critical care medicine.

[34]  R. Wise,et al.  Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. , 2003, The Journal of rheumatology.

[35]  Z. Yıldırım,et al.  Impaired cardiac autonomic functions in patients with environmental asbestos exposure: a study of time domain heart rate variability. , 2003, Journal of electrocardiology.

[36]  P. Rouleau,et al.  Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003, The Journal of Immunology.

[37]  A. Nicholson,et al.  Interstitial vascularity in fibrosing alveolitis. , 2003, American journal of respiratory and critical care medicine.

[38]  M. Yanagisawa,et al.  Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[39]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[40]  M. Yanagisawa,et al.  Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[41]  N. Voelkel,et al.  Genomic approaches to research in pulmonary hypertension , 2001, Respiratory research.

[42]  X. Zeng,et al.  NBP is the p53 homolog p63. , 2001, Carcinogenesis.

[43]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[44]  J. Preisler,et al.  Screening of pulmonary hypertension in chronic obstructive pulmonary disease and silicosis by discriminant functions. , 1992, The European respiratory journal.